Literature DB >> 35035091

Rescuing emergency cases of COVID-19 patients: An intelligent real-time MSC transfusion framework based on multicriteria decision-making methods.

M A Alsalem1, O S Albahri1, A A Zaidan1, Jameel R Al-Obaidi2, Alhamzah Alnoor3, A H Alamoodi1, A S Albahri4, B B Zaidan1, F M Jumaah5.   

Abstract

Mesenchymal stem cells (MSCs) have shown promising ability to treat critical cases of coronavirus disease 2019 (COVID-19) by regenerating lung cells and reducing immune system overreaction. However, two main challenges need to be addressed first before MSCs can be efficiently transfused to the most critical cases of COVID-19. First is the selection of suitable MSC sources that can meet the standards of stem cell criteria. Second is differentiating COVID-19 patients into different emergency levels automatically and prioritising them in each emergency level. This study presents an efficient real-time MSC transfusion framework based on multicriteria decision-making(MCDM) methods. In the methodology, the testing phase represents the ability to adhere to plastic surfaces, the upregulation and downregulation of specific surface protein markers and finally the ability to differentiate into different kinds of cells. In the development phase, firstly, two scenarios of an augmented dataset based on the medical perspective are generated to produce 80 patients with different emergency levels. Secondly, an automated triage algorithm based on a formal medical guideline is proposed for real-time monitoring of COVID-19 patients with different emergency levels (i.e. mild, moderate, severe and critical) considering the improvement and deterioration procedures from one level to another. Thirdly, a unique decision matrix for each triage level (except mild) is constructed on the basis of the intersection between the evaluation criteria of each emergency level and list of COVID-19 patients. Thereafter, MCDM methods (i.e. analytic hierarchy process [AHP] and vlsekriterijumska optimizcija i kaompromisno resenje [VIKOR]) are integrated to assign subjective weights for the evaluation criteria within each triage level and then prioritise the COVID-19 patients on the basis of individual and group decision-making(GDM) contexts. Results show that: (1) in both scenarios, the proposed algorithm effectively classified the patients into four emergency levels, including mild, moderate, severe and critical, taking into consideration the improvement and deterioration cases. (2) On the basis of experts' perspectives, clear differences in most individual prioritisations for patients with different emergency levels in both scenarios were found. (3) In both scenarios, COVID-19 patients were prioritised identically between the internal and external group VIKOR. During the evaluation, the statistical objective method indicated that the patient prioritisations underwent systematic ranking. Moreover, comparison analysis with previous work proved the efficiency of the proposed framework. Thus, the real-time MSC transfusion for COVID-19 patients can follow the order achieved in the group VIKOR results.
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2021.

Entities:  

Keywords:  AHP; COVID-19; Mesenchymal stem cell therapy; Multicriteria decision-making; VIKOR

Year:  2022        PMID: 35035091      PMCID: PMC8741536          DOI: 10.1007/s10489-021-02813-5

Source DB:  PubMed          Journal:  Appl Intell (Dordr)        ISSN: 0924-669X            Impact factor:   5.019


  61 in total

1.  The use of analytic hierarchy process for measuring the complexity of medical diagnosis.

Authors:  Ofir Ben-Assuli; Nanda Kumar; Ofer Arazy; Itamar Shabtai
Journal:  Health Informatics J       Date:  2019-01-23       Impact factor: 2.681

2.  Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial.

Authors:  Christoph D Spinner; Robert L Gottlieb; Gerard J Criner; José Ramón Arribas López; Anna Maria Cattelan; Alex Soriano Viladomiu; Onyema Ogbuagu; Prashant Malhotra; Kathleen M Mullane; Antonella Castagna; Louis Yi Ann Chai; Meta Roestenberg; Owen Tak Yin Tsang; Enos Bernasconi; Paul Le Turnier; Shan-Chwen Chang; Devi SenGupta; Robert H Hyland; Anu O Osinusi; Huyen Cao; Christiana Blair; Hongyuan Wang; Anuj Gaggar; Diana M Brainard; Mark J McPhail; Sanjay Bhagani; Mi Young Ahn; Arun J Sanyal; Gregory Huhn; Francisco M Marty
Journal:  JAMA       Date:  2020-09-15       Impact factor: 56.272

3.  Role of biological Data Mining and Machine Learning Techniques in Detecting and Diagnosing the Novel Coronavirus (COVID-19): A Systematic Review.

Authors:  A S Albahri; Rula A Hamid; Jwan K Alwan; Z T Al-Qays; A A Zaidan; B B Zaidan; A O S Albahri; A H AlAmoodi; Jamal Mawlood Khlaf; E M Almahdi; Eman Thabet; Suha M Hadi; K I Mohammed; M A Alsalem; Jameel R Al-Obaidi; H T Madhloom
Journal:  J Med Syst       Date:  2020-05-25       Impact factor: 4.460

Review 4.  Production of Mesenchymal Stem Cells Through Stem Cell Reprogramming.

Authors:  Ahmed Abdal Dayem; Soo Bin Lee; Kyeongseok Kim; Kyung Min Lim; Tak-Il Jeon; Jaekwon Seok; And Ssang-Goo Cho
Journal:  Int J Mol Sci       Date:  2019-04-18       Impact factor: 5.923

Review 5.  Mesenchymal Stem Cells from the Wharton's Jelly of the Human Umbilical Cord: Biological Properties and Therapeutic Potential.

Authors:  Luigi Marino; Maria Antonietta Castaldi; Rosa Rosamilio; Enrico Ragni; Rosa Vitolo; Caterina Fulgione; Salvatore Giovanni Castaldi; Bianca Serio; Rosario Bianco; Maurizio Guida; Carmine Selleri
Journal:  Int J Stem Cells       Date:  2019-07-31       Impact factor: 2.500

6.  Adipose-derived stromal stem cells (ASCs) as a new regenerative immediate therapy combating coronavirus (COVID-19)-induced pneumonia.

Authors:  Pietro Gentile; Aris Sterodimas
Journal:  Expert Opin Biol Ther       Date:  2020-04-29       Impact factor: 4.388

7.  Stem cell therapy in COVID-19: Pooled evidence from SARS-CoV-2, SARS-CoV, MERS-CoV and ARDS: A systematic review.

Authors:  Saniya Mahendiratta; Seema Bansal; Phulen Sarma; Harish Kumar; Gajendra Choudhary; Subodh Kumar; Ajay Prakash; Rakesh Sehgal; Bikash Medhi
Journal:  Biomed Pharmacother       Date:  2021-01-28       Impact factor: 7.419

Review 8.  Regenerative Medicine in COVID-19 Treatment: Real Opportunities and Range of Promises.

Authors:  Arefeh Basiri; Zahra Pazhouhnia; Nima Beheshtizadeh; Mahdieh Hoseinpour; Amene Saghazadeh; Nima Rezaei
Journal:  Stem Cell Rev Rep       Date:  2021-02       Impact factor: 5.739

9.  Clinical Findings of COVID-19 Patients Admitted to Intensive Care Units in Guangdong Province, China: A Multicenter, Retrospective, Observational Study.

Authors:  Yonghao Xu; Zhiheng Xu; Xuesong Liu; Lihua Cai; Haichong Zheng; Yongbo Huang; Lixin Zhou; Linxi Huang; Yun Ling; Liehua Deng; Jianwei Li; Sibei Chen; Dongdong Liu; Zhimin Lin; Liang Zhou; Weiqun He; Nanshan Zhong; Xiaoqing Liu; Yimin Li
Journal:  Front Med (Lausanne)       Date:  2020-10-19

10.  Evaluation of the Effectiveness of Surveillance and Containment Measures for the First 100 Patients with COVID-19 in Singapore - January 2-February 29, 2020.

Authors:  Yixiang Ng; Zongbin Li; Yi Xian Chua; Wei Liang Chaw; Zheng Zhao; Benjamin Er; Rachael Pung; Calvin J Chiew; David C Lye; Derrick Heng; Vernon J Lee
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2020-03-20       Impact factor: 17.586

View more
  1 in total

1.  Multi-criteria decision-making for coronavirus disease 2019 applications: a theoretical analysis review.

Authors:  M A Alsalem; A H Alamoodi; O S Albahri; K A Dawood; R T Mohammed; Alhamzah Alnoor; A A Zaidan; A S Albahri; B B Zaidan; F M Jumaah; Jameel R Al-Obaidi
Journal:  Artif Intell Rev       Date:  2022-01-27       Impact factor: 9.588

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.